Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Optimal Dose of Ticagrelor（90 mg qd）and Double Standard-dose Clopidogrel on Platelet Aggregation in Clopidogrel Resistance's Patients With Coronary Heart Disease

NCT03614832 is registered in ClinicalTrials.gov with First Affiliated Hospital of Harbin Medical University as lead sponsor.

NCT NCT03614832
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03614832 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Optimal Dose of Ticagrelor（90 mg qd）and Double Standard-dose Clopidogrel on Platelet Aggregation in Clopidogrel Resistance's Patients With Coronary Heart Disease
Lead sponsor
First Affiliated Hospital of Harbin Medical University
Phase
Phase 4
Overall status
Unknown status
Start date
May 1, 2018
Completion date
October 1, 2019
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

platelet reactivity